Top 5 Most Read RNS's on Vox Markets for Wednesday 19th April 2023
Episode 1339, Apr 19, 2023, 06:51 AM
Top 5 Most Read RNS's on Vox Markets for Wednesday 19th April 2023
1. Kistos Holdings #KIST - Agreement to Acquire Mime Petroleum A.S
On completion, the acquisition will add 24 MMboe of 2P reserves and will also add over 2,000 boe/d of production immediately.
Group production in 2023 will be in the range of 8,500 and 10,500boe/d.
The consideration for the transaction is US$1 plus the issue of up to 6 million warrants exercisable into new Kistos ordinary shares at a price of 385p
2. Amigo Holdings #AMGO - Statement re. share price movement
Amigo Holdings has noted the recent movement in the Company's share price and confirms that it knows of no reason for this increase.
The board continues to implement the fallback solution, which is the orderly wind-down of the business, which is expected to result in no value attributable to shareholders once the wind-down is completed.
3. Angus Energy #ANGS - Finalisation of Management Changes & Options issue
Further to the announcement of 2 March 2023 and Angus's vision of becoming a significant player in the aggregation, production and storage of gas, the Company is pleased to finalise the appointment of Richard Herbert as Chief Executive Director, George Lucan as Executive Chairman and Patrick Clanwilliam as Non-Executive Director.
4. Audioboom Group #BOOM - Q1 Trading Update
Q1 revenue, in line with expectations, of US$15.4 million. This was, as expected, lower than Q1 2022 (US$19.5 million).
Strong management and cost control enabled maintenance of profitable operations despite market conditions with Q1 adjusted EBITDA(1) profit of US$0.2 million.
Group cash at 31 March 2023 of US$5.1 million (31 December 2022: US$8.1 million).
5. Angle #AGL - ANGLE announces partnership with BioView
ANGLE announce it has signed an agreement with BioView to develop a liquid biopsy circulating tumor cell (CTC) HER2 assay for breast cancer utilising ANGLE's FDA cleared Parsortix® PC1 Clinical System to harvest CTCs and BioView's automated microscopy systems and software to detect and assess the HER2 expression and/or gene amplification in CTCs.
1. Kistos Holdings #KIST - Agreement to Acquire Mime Petroleum A.S
On completion, the acquisition will add 24 MMboe of 2P reserves and will also add over 2,000 boe/d of production immediately.
Group production in 2023 will be in the range of 8,500 and 10,500boe/d.
The consideration for the transaction is US$1 plus the issue of up to 6 million warrants exercisable into new Kistos ordinary shares at a price of 385p
2. Amigo Holdings #AMGO - Statement re. share price movement
Amigo Holdings has noted the recent movement in the Company's share price and confirms that it knows of no reason for this increase.
The board continues to implement the fallback solution, which is the orderly wind-down of the business, which is expected to result in no value attributable to shareholders once the wind-down is completed.
3. Angus Energy #ANGS - Finalisation of Management Changes & Options issue
Further to the announcement of 2 March 2023 and Angus's vision of becoming a significant player in the aggregation, production and storage of gas, the Company is pleased to finalise the appointment of Richard Herbert as Chief Executive Director, George Lucan as Executive Chairman and Patrick Clanwilliam as Non-Executive Director.
4. Audioboom Group #BOOM - Q1 Trading Update
Q1 revenue, in line with expectations, of US$15.4 million. This was, as expected, lower than Q1 2022 (US$19.5 million).
Strong management and cost control enabled maintenance of profitable operations despite market conditions with Q1 adjusted EBITDA(1) profit of US$0.2 million.
Group cash at 31 March 2023 of US$5.1 million (31 December 2022: US$8.1 million).
5. Angle #AGL - ANGLE announces partnership with BioView
ANGLE announce it has signed an agreement with BioView to develop a liquid biopsy circulating tumor cell (CTC) HER2 assay for breast cancer utilising ANGLE's FDA cleared Parsortix® PC1 Clinical System to harvest CTCs and BioView's automated microscopy systems and software to detect and assess the HER2 expression and/or gene amplification in CTCs.